NasdaqGS:SDGRHealthcare Services
Schrödinger (SDGR): Revisiting Valuation After Analyst Upgrades and a Strategic Shift Toward Software
BofA Securities’ recent upgrade of Schrödinger (SDGR), alongside KeyBanc’s reiterated positive stance, centers on one big shift: the company is leaning harder into its higher margin software business and away from cash hungry drug programs.
See our latest analysis for Schrödinger.
The market seems to be cautiously warming to that story, with a 7 day share price return of 5.63% and a 30 day share price return of 7.42%. However, the year to date share price return remains negative and long term...